Endocrinology and Metabolism

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea

Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim

Endocrinol Metab. 2020;35(2):329-338. Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.329

Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim

Endocrinology and Metabolism. 2020;35(2):329-338

Link1

Link2 Link3

PO184 COMPARISON OF VILDAGLIPTIN AS AN ADD-ON THERAPY AND SULFONYLUREA DOSE-INCREASING THERAPY IN PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING METFORMIN AND SULFONYLUREA

A.R. Hong, J. Lee, E.J. Ku, Y. Hwangbo, K.M. Kim, J.H. Moon, S.H. Choi, H.C. Jang, S. Lim

Diabetes Research and Clinical Practice. 2014;106:S141

Link1 Link2

Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial

A Ram Hong, Jeun Lee, Eu Jeong Ku, Yul Hwangbo, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang, Soo Lim

Diabetes Research and Clinical Practice. 2015;109(1):141-148

Link1 Link2

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial

S. Ross, C. Thamer, J. Cescutti, T. Meinicke, H. J. Woerle, U. C. Broedl

Diabetes, Obesity and Metabolism. 2015;17(7):699-702

Link1 Link2

Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

Luigi F. Meneghini, Louise Traylor, Sherwyn L. Schwartz

Endocrine Practice. 2010;16(4):588-599

Link1 Link2 Link3

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study

S Halimi, M.A Le Berre, V Grangé

Diabetes Research and Clinical Practice. 2000;50(1):49-56

Link1 Link2

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Eirik Søfteland, Juris J. Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C. Broedl

Diabetes Care. 2016;40(2):201-209

Link1 Link2

Link3

Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study

Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh

Diabetes Research and Clinical Practice. 2019;151:65-73

Link1 Link2

PO173 EFFICACY AND SAFETY OF ANAGLIPTIN COMPARED WITH SITAGLIPTIN AS AN ADD-ON FOR PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY

S.-M. Jin, S.W. Park, K.-H. Yoon, M.-K. Lee

Diabetes Research and Clinical Practice. 2014;106:S135-S136

Link1 Link2

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

M. A. Nauck, S. Del Prato, S. Durán-García, K. Rohwedder, A. M. Langkilde, J. Sugg, S. J. Parikh

Diabetes, Obesity and Metabolism. 2014;16(11):1111-1120

Link1 Link2